As tuberculosis continues to place a significant healthcare and socioeconomic burden on the world, the World Health Organization (WHO) has pushed the need for increasing the availability of molecular diagnostics to help eliminate the epidemic by 2030. Mycobacterium tuberculosis (TB) is the leading cause of infectious disease deaths worldwide. In 2019, TB infected about 1.7 billion people, with an estimated 10 million new cases and 1.4 million deaths reported.1 This includes approximately 815,000 tuberculosis infections in people living with HIV/AIDS and 208,000 deaths in this population.1